Superior penile girth retention with stromal vascular fraction-enriched autologous fat grafting: a retrospective 1-year comparative study.
Ivanenko O., Gheiler E., Sforza M.
Laboratory Study with a reported sample of 50, published in Transl Androl Urol (2026) — summary generated from the PubMed abstract.
Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.
- Level A · Stronger Clinical Evidence
- Level B · Emerging clinical evidence with positive signals
- Level C · Early human research exploring benefits
- Level D · Scientific groundwork from lab and animal studies
- Emerging · Emerging topic under active research
This page is generated from the PubMed record. The Thai description is an automated summary of bibliographic fields and the abstract, not a full translation, and is not medical advice.
- Study type
- Laboratory Study
- Journal
- Transl Androl Urol (2026)
- Country
- China
- Reported sample size
- 50
- Source database
- PubMed
- PMID
- 42582889
- DOI
- 10.21037/tau-2026-0415
Abstract (original English)
Fat resorption limits long-term outcomes of fat grafting for penile girth augmentation. Stromal vascular fraction (SVF)-enriched fat may improve graft survival by promoting angiogenesis, modulating inflammation, and via other paracrine effects. To our knowledge, no prior studies employed SVF for penile aesthetic procedures. In this retrospective non-randomized study, we aimed to assess the safety and clinical performance of SVF-enriched fat grafting versus Coleman fat. For the treatment group (n=50), protocol key steps included liposuction, non-enzymatic extraction of SVF via a novel device, fat enrichment, and graft injection, avoiding the corpora cavernosa. The Coleman fat group (n=38) received conventional grafting. Penile girth and length (flaccid and erect) and International Index of Erectile Function-5 scores were evaluated at baseline and at 1, 3, 6, and 12 months. Satisfaction was recorded at 12 months. Men with mild erectile dysfunction (n=10 and n=17 in the Coleman fat and treatment groups, respectively) also completed the full questionnaire about erection. The primary outcome was change in penile girth. Exploratory outcomes included change in penile length, erectile function, and patient-reported satisfaction with the procedure. At 12 months, the treatment group showed significantly higher volume retention across all measurements (P<0.001), greater satisfaction (4.2/
What this study does not prove
- • This study does not prove SVF is an approved treatment or a replacement for standard care.
- • This is preclinical work; animal or laboratory results cannot be applied to humans.
Evidence level
Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.
How we grade evidenceBrowse all related research
Filter the research library by this study's title keywords, author, or publication year.